Efficacy of post-exposure treatment of yellow fever with ribavirin in a hamster model of the disease

American Journal of Tropical Medicine and Hygiene

Volumn 71, Issue 3, 2004, Pages 306-312

  Sbrana, Elena ^a   Xiao, Shu Yuan ^a   Guzman, Hilda ^a   Ye, Mengyi ^a   Travassos Da Rosa, Amelia P A ^a   Tesh, Robert B ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; RIBAVIRIN;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC HEPATITIS; DRUG EFFICACY; FATTY LIVER; FEMALE; HAMSTER; HEPATITIS C; LIVER INJURY; NONHUMAN; SPLEEN INJURY; SURVIVAL; YELLOW FEVER;

ANIMALIA; CRICETINAE; HEPATITIS C VIRUS; RNA VIRUSES;

EID: 4544346116     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2004.71.306     Document Type: Article

References (25)

1. McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM, Elliott LH, Belmont-Williams R, 1986. Lassa fever: effective therapy with ribavirin. New Engl J Med 314: 20-26.
2. Enria DA, Briggiler AM, Levis S, Vallejos D, Maiztegui JI, Canonico PG, 1987. Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever. Antiviral Res 7: 353-359.
3. Kilgore PE, Ksiazek TG, Rollin PE, Mills JN, Villagra MR, Montenegro MJ, Costales MA, Paredes LC, Peters CJ, 1997. Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. Clin Infect Dis 24: 718-722.
4. Barry M, Russi M, Armstrong L, Geller D, Tesh RB, Dembry L, Gonzalez JP, Khan AS, Peters CF, 1995. Treatment of a laboratory-acquired Sabia virus infection. N Eng J Med 333: 294-296.
5. Huggins JW, Hsiang CM, Cosgriff TM, Guang MY, Smith JI, Wu ZO, LeDuc JW, Zheng ZM, Meegan JM, Wang QN, 1991. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis 164: 1119-1127.
6. Fisher-Hoch SP, Khan JA, Rehman S, Mirza S, Khurshid M, McCormick JB, 1995. Crimean-Congo haemorrhagic fever treated with oral ribavirin. Lancet 346: 472-475.
7. Mardani M, Jahromi MK, Naieni KH, Zeinali M, 2003. The efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Iran (CCHF). Clin Infect Dis 36: 1613-1618.
8. Huggins JW, 1989. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad spectrum antiviral drug. Rev Infect Dis 11: S750-S761.
9. Monath TP, Brinker KR, Chandler FW, Kemp GE, Cropp CB, 1981. Pathophysiologic correlations in a rhesus monkey model of yellow fever. Am J Trop Med Hyg 30: 431-443.
10. Neyts J, Meerbach A, McKenna P, de Clercq E, 1996. Use of yellow fever vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections. Antiviral Res 30: 125-132.
11. Crance JM, Scaramozzino N, Jouan A, Garin D, 2003. Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. Antiviral Res 58: 73-79.
12. Buckwold VE, Wei J, Wenzel-Mathers M, Russell J, 2003. Synergistic in vitro interactions between alpha interferon and ribavirin against bovine viral diarrhea virus and yellow fever virus as surrogate models of hepatitis C virus replication. Antimicrob Agents Chemother 47: 2293-2298.
13. Tesh RB, Guzman H, Travassos da Rosa APA, Vasconcelos PFC, Dias LB, Bunnell JE, Zhang H, Xiao SY, 2001. Experimental yellow fever virus infection in the golden hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies. J Infect Dis 183: 1431-1436.
14. Xiao SY, Zhang H, Guzman H, Tesh RB, 2001. Experimental yellow fever virus infection in the golden hamster (Mesocricetus auratus). II. Pathology. J Infect Dis 183: 1437-1444.
15. Reed LJ, Muench H, 1938. A simple method of estimating fifty percent end points. Am J Hyg 27: 493-497.
16. Clarke DH, Casals J, 1958. Techniques for hemagglutination and hemagglutination-inhibition of arthropod-borne viruses. Am J Trop Med Hyg 7: 561-573.
17. Robertson SE, Hull BP, Tomori O, Beleo O, LeDuc JW, Esteves K, 1996. Yellow fever: a decade of reemergence. JAMA 276: 1157-1162.
18. Monath TP, 1997. Epidemiology of yellow fever: current status and speculations on future trends. Saluzzo JF, Dodet B, eds. Factors in the Emergence of Arbovirus Diseases. Paris: Elsevier, 143-165.
19. Xiao S-Y, Guzman H, Travassos da Rosa APA, Zhu H-B, Tesh RB, 2003. Alteration of clinical outcome and histopathology of yellow fever virus infection in a hamster model by previous infection with heterologous flaviviruses. Am J Trop Med Hyg 68: 695-703.
20. McArthur MA, Suderman MT, Mutebi J-P, Xiao S-Y, Barrett ADT, 2003. Molecular characterization of a hamster viscerotropic strain of yellow fever virus. J Virol 77: 1462-1468.
21. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB, 1997. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 26: 473-477.
22. Lau JYN, Tam RC, Liang TJ, Hong Z, 2002. Mechanisms of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35: 1002-1009.
23. Crotty S, Cameron C, Andino R, 2002. Ribavirin's antiviral mechanism of action: lethal mutagenesis? J Mol Med 80: 86-95.
24. Inouye RT, Panther LA, Hay CM, Hammer SM, 2002. Antiviral agents. Richmond DD, Whitley RJ, Hayden FG, eds. Clinical Virology. Second edition. Washington, DC: American Society for Microbiology Press, 171-242.
25. Monath TP, Tsai TF, 2002. Flaviviruses. Richman DD, Whitley RJ, Hayden FG, eds. Clinical Virology. Second edition. Washington, DC: American Society for Microbiology Press, 1097-1151.